Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Jemperli (dostarlimab-gxly) is a PD-1 blocking antibody that helps the immune system recognize and attack cancer cells by blocking a checkpoint protein that tumors use to evade immune detection.
Jemperli, combined with carboplatin and paclitaxel followed by Jemperli monotherapy, is FDA-approved for adult patients with primary advanced or recurrent endometrial cancer. As a single agent, it is also approved for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after platinum-based treatment, and for dMMR solid tumors that have progressed after prior treatment with no satisfactory alternative options.
Dostarlimab binds to PD-1 receptors on T-cells, blocking their interaction with PD-L1/PD-L2 on tumor cells, which restores the immune system's ability to identify and destroy cancer cells.
For primary advanced or recurrent endometrial cancer, the dose is 500 mg IV every 3 weeks for 6 doses as part of chemotherapy combination, then 1000 mg IV every 6 weeks as monotherapy for up to 3 years. For dMMR indications, dosing is 500 mg IV every 3 weeks for 4 doses, then 1000 mg IV every 6 weeks, as determined by the treating oncologist.
As a PD-1 immune checkpoint inhibitor, Jemperli can cause immune-mediated adverse reactions affecting multiple organ systems, which may be severe or fatal and can occur even after treatment discontinuation.
Monitor for new or worsening respiratory symptoms; manage with corticosteroids and treatment interruption as needed.
Monitor for diarrhea or signs of colitis.
Monitor liver function tests and thyroid/other hormone levels periodically during treatment.
Monitor kidney function and for skin changes throughout treatment.
Monitor during and after infusion for hypersensitivity reactions.
Jemperli can cause fetal harm. Effective contraception is required during treatment and for 4 months after the final dose; breastfeeding is not recommended during this period.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Jemperli (dostarlimab-gxly) is manufactured by GlaxoSmithKline and is approved for multiple endometrial cancer indications as well as dMMR solid tumors.
Import of Jemperli through a Named Patient Program requires a valid prescription from the treating oncologist, confirmation of diagnosis and biomarker (dMMR/MSI-H) status where relevant, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Jemperli directly from GlaxoSmithKline's authorized supply chain to ensure product authenticity and regulatory compliance.
Jemperli is sourced through verified, GDP-compliant, cold-chain channels from GlaxoSmithKline's authorized supply chain to ensure authenticity and quality.
Jemperli should be stored refrigerated at 2°C to 8°C. Do not freeze.
Once sourced, Jemperli is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Jemperli through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading oncology centers in Mumbai support endometrial cancer diagnosis and treatment coordination for Jemperli access.
Delhi's major cancer hospitals assist patients with biomarker testing and prescription support for Jemperli.
Bangalore's oncology network offers access to dMMR/MSI-H testing and treatment planning for eligible patients.
Chennai-based specialists coordinate Jemperli access alongside comprehensive gynecologic oncology care.
Hyderabad's cancer care institutions support patients pursuing Jemperli therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Jemperli.
Pune-based oncologists assist with biomarker testing and Jemperli treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Jemperli.
Kochi's oncology units assist patients with the documentation needed for Jemperli access.
Chandigarh's cancer care centers support Jemperli treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Jemperli access process.
Lucknow-based cancer centers assist patients pursuing Jemperli therapy.
Bhubaneswar's oncology institutions support access to Jemperli for eligible patients.
Guwahati's specialists help coordinate Jemperli access for patients across the Northeast.
Patients in other cities across India can also access Jemperli through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
